His termination letter said 'without cause'—until he tried to negotiate
A top sales executive says he was pushed out days before a key billing deadline after flagging alleged overbilling — and then branded "with cause" after he asked for his pay.
Alejandro Villageliu, former Executive Vice President – Head of Enterprise at RxVantage, Inc., is suing the company in federal court in California, accusing it of retaliating after he raised concerns about how the firm was billing some of its biggest pharmaceutical clients. The case was filed on January 23, 2026, in the U.S. District Court for the Central District of California.
According to the court filing, Villageliu joined RxVantage as an independent contractor in or around April 2020 and became a full-time executive on November 1, 2020. He reported directly to the chief executive and later to the chief marketing officer, and he says he helped more than triple the company's enterprise client base and deliver a "record-breaking" fourth quarter in 2023.
The trouble, he says, began in early 2025. Villageliu alleges that in or around January 2025, he discovered that numerous pharmaceutical clients were being billed for software licenses they did not need. The filing says some clients were charged for licenses assigned to former sales representatives and to people who were not in sales roles at all, including nurse educators and other non-sales staff. In a sample covering roughly half of the company's multi-specialty business, he claims every client was being overbilled, with some paying for more than 200 unneeded licenses.
On or about February 14, 2025, Villageliu says he presented these findings to senior leadership, including the chief executive, chief marketing officer, chief financial officer and the senior vice president of client services. The filing describes the reaction as "immediately negative," with leadership more focused, in his telling, on finding flaws in his analysis than on fixing the billing practices.
After that meeting, the tone at work allegedly shifted. Villageliu says he was quietly cut out of VP of Sales interviews without notice, blocked from presenting his recommendations to other leaders and left without responses to key emails. Human resources and other executives began going around him, he claims, by directing his executive assistant to cancel candidate meetings he had set and reassign administrative control of software tools he and his team used.
As the March 31 quarterly "true-up" approached, Villageliu says he revisited the data. On or about March 23, 2025, he told the senior vice president of client services that three more large pharmaceutical clients had been overbilled, linked to more than 700 overactivated licenses. Three days later, during a one-on-one meeting, the chief marketing officer allegedly told that executive he did not want Villageliu making any further presentations to the finance chief.
On or about March 28, 2025, three days before the true-up date, Villageliu was fired, according to the filing. He says he was given no reason and no severance.
The dispute did not end there. Villageliu says that on or about April 1, 2025, he received a termination letter stating his departure was "without cause" and attaching a "Severance Commission" document. He then sought a copy of his commission records and asserted that he was owed about $65,000 under a written commission plan, which defined commissions as "earned" when a customer agreement was fully executed while he was employed.
Later that month, on or about April 21, 2025, company lawyers told him that his termination was being changed to "with cause" because he had tried to negotiate an exit package, according to the filing. Villageliu says he has never been paid the commissions he believes he earned.
The suit raises claims of retaliation, wrongful termination, breach of contract and failure to pay wages at separation. No court has yet ruled on the allegations, and RxVantage has not had its side of the story tested at trial.
